A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Recruiting now · Phase 3

Conditions studied: Uterine Fibroids, Endometriosis

In brief

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.

Key facts

Study ID
NCT05862272
Run by
Sumitomo Pharma Switzerland GmbH
People needed
1000
Starts
2023-08-14
Expected to finish
2030-09-01
Last updated by the study team
2025-08-06

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.